Clinical Journal of Gastroenterology

, Volume 6, Issue 3, pp 226–230 | Cite as

Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: case series and review of the literature

  • Naoki Minami
  • Hiroshi Nakase
  • Takuya Yoshino
  • Satoshi Yamada
  • Takahiko Toyonaga
  • Yusuke Honzawa
  • Minoru Matsuura
  • Tsutomu Chiba
Case Report

Abstract

Takayasu arteritis (TA) and inflammatory bowel disease (IBD) are chronic inflammatory disorders. The mechanisms underlying these diseases are not precisely known, but tumor necrosis factor alpha (TNF-α) is considered to have an important role in the pathophysiology of both TA and IBD. Simultaneous occurrence of both TA and IBD is rare. Our first case was a 42-year-old woman with TA and inflammatory bowel disease unclassified. The patient was refractory to treatment with an immunomodulator, and infliximab (IFX) was started. After starting IFX, clinical remission was achieved and maintained for 2 years. The second case was a 34-year-old woman with TA accompanied by Crohn’s disease. Because her abdominal symptoms relapsed despite treatment with an immunomodulator, IFX was started. Both diseases were well controlled for 2 years by scheduled maintenance therapy with IFX. Relapse of the TA required increased doses of IFX at shorter intervals, which relieved her symptoms. Overall, we identified nine cases for which IFX was effective, including our 2 cases. They may demonstrate the efficacy of IFX for IBD with TA and emphasize the role of TNF-α in the pathophysiology.

Keywords

Takayasu arteritis Inflammatory bowel disease Tumor necrosis factor alpha Infliximab 

Notes

Acknowledgments

None.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55(7):481–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Kusunoki R, Ishihara S, Sato M, Sumita Y, Mishima Y, Okada M, et al. Rare case of Takayasu’s arteritis associated with Crohn’s disease. Intern Med. 2011;50(15):1581–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.PubMedCrossRefGoogle Scholar
  5. 5.
    Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50(7):2296–304.PubMedCrossRefGoogle Scholar
  6. 6.
    Calderón R, Estrada S, Ramírez de la Piscina P, Salvador M, Zabaleta S, Enciso C, et al. Infliximab in a patient with refractory ileocolic Crohn’s disease and Takayasu arteritis. Rev Esp Enferm Dig. 2010;102(2):145–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Gecse K, Ruzsa Z, Nagy F, Wittmann T, Molnár T. Successful infliximab treatment in a patient with Takayasu arteritis associated with ulcerative colitis or migration does not override genetics. Inflamm Bowel Dis. 2011;17(7):E69–70. doi: 10.1002/ibd.21731.PubMedCrossRefGoogle Scholar
  8. 8.
    Kellermayer R, Jain AK, Ferry G, Deguzman MM, Guillerman RP. Clinical challenges and images in GI. Aortitis as a rare complication of Crohn’s disease. Gastroenterology. 2008;134(3):668, 898.Google Scholar
  9. 9.
    Judah JR, Hammond CJ, Polyak SF, Drane WE, Valentine JF. The coexistence of Crohn’s disease and Takayasu arteritis: diagnosis and treatment of combined disease in three patients. Pract Gastroenterol. 2009;3:50–8.Google Scholar
  10. 10.
    Ratuapli S, Mazlumzadeh M, Gurudu S, Money S, Heigh R. Coexisting Crohn’s disease and Takayasu’s arteritis in two patients treated with anti-TNF-α therapies. Case Rep Gastroenterol. 2010;4(1):35–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Katoh N, Kubota M, Shimojima Y, Ishii W, Matsuda M, Akamatsu T, et al. Takayasu’s arteritis in a patient with Crohn’s disease: an unexpected association during infliximab therapy. Intern Med. 2010;49(2):179–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Horai Y, Satoru O, Lapalme-Remis S, Sumiyoshi R, Nakashima Y, Suzuki T, et al. Takayasu arteritis developing during treatment of ulcerative colitis with infliximab. Mod Rheumatol. 2012.Google Scholar
  13. 13.
    Morita Y, Yamamura M, Suwaki K, Mima A, Ishizu T, Hirohata M, et al. Takayasu’s arteritis associated with ulcerative colitis; genetic factors in this association. Intern Med. 1996;35(7):574–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–29.PubMedCrossRefGoogle Scholar
  15. 15.
    Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev. 2011;11(1):61–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Naoki Minami
    • 1
  • Hiroshi Nakase
    • 1
  • Takuya Yoshino
    • 1
  • Satoshi Yamada
    • 1
  • Takahiko Toyonaga
    • 2
  • Yusuke Honzawa
    • 1
  • Minoru Matsuura
    • 1
  • Tsutomu Chiba
    • 1
  1. 1.Department of Gastroenterology and Hepatology, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.The Third Department of Internal MedicineKansai Medical UniversityHirakataJapan

Personalised recommendations